Author: admin

From Section 8 to CEO: Dannielle Thomas Launches Building Foundations and New Program Passion into Profits to Inspire and Empower Entrepreneurs

Dannielle Thomas, a powerhouse entrepreneur, financial advisor, nonprofit leader, and founder of Building Foundations, is turning her extraordinary life journey into a mission to help others break through limitations and achieve both business success and spiritual growth. From her humble beginnings in Section 8 housing to building a six-figure career and now stepping onto the path toward seven and eight figures, Thomas’s story is a testament to resilience, faith, and fearless determination.

Raised by a single mother in a home where hot dogs, beans and weenies, and spaghetti were staple meals, Thomas grew up believing in the power of God and big dreams, even when her reality told a different story. Her earliest inspiration came from a wealthy family she called the “Hargraves,” who opened her eyes to the world of business and possibility from an incredibly young age.

“I used to write out my business ideas as a teenager, but it felt like a pipe dream,” recalls Thomas. “For years, I didn’t know where to start. Now, I not only know how; I have the blueprint to help others do it too!”

Despite academic struggles and financial hardship, Thomas pushed forward, working multiple jobs while navigating homelessness and life-changing setbacks. She eventually broke into the financial services industry, becoming a financial advisor in record-breaking time and earning a six-figure income by her late 20s. But even at the height of comfort, something was missing: it was her childhood dream of entrepreneurship.

After her divorce, Thomas decided it was time to stop postponing her dreams. That’s when she connected with business mentor Mike Barron, who provided the mindset shift and proven framework that would allow her to scale beyond six figures and toward her ultimate goals.

Through Building Foundations, Thomas is now launching her flagship program, Passion into Profits, designed to help aspiring and established entrepreneurs to realize their true potential in business and scale businesses using the exact strategies and structures that have fueled her own success.

Alongside her business ventures, Thomas is also the founder of a nonprofit ministry dedicated to helping young adults deepen their spiritual development and walk in their God given purpose.

“Since I was a young girl, I knew that God had a major calling on my life to help many people be set free,” Thomas says. “Through my ministry, I’m helping young adults understand their identity in Christ so they can step fully into their calling.”

“Godspeed is my catchphrase because I know God is the driving force behind my success,” Thomas adds. “I want to take people with me to the top and show them that failure isn’t the end, it’s the launchpad.”

Through Building Foundations and Passion into Profits, Thomas helps entrepreneurs achieve financial breakthroughs while equipping them spiritually to walk in power and authority. Her upcoming book, Failing Up, will help people face their fears by understanding that there is power in overcoming life’s obstacles.

“I know what it’s like to feel stuck, to feel like the odds are stacked against you,” Thomas says. “But I also know that with the right guidance, both practical and spiritual, you can completely change your life. I’m living proof.”

Thomas is currently scaling her business to reach seven to eight figures, and she is committed to making sure others reach their mountaintop alongside her.

About Dannielle Thomas

Dannielle Thomas is an entrepreneur, financial advisor, nonprofit leader, speaker, and founder of Building Foundations, a business consulting firm dedicated to helping people build strong personal, spiritual, and business foundations for lasting success. She is also the founder of a nonprofit ministry that equips young adults for spiritual growth and freedom in Christ. From growing up in Section 8 housing to building a six-figure career, Thomas’s journey is a story of resilience, faith, and relentless pursuit of success. She is the upcoming author of Failing Up and is on a mission to help others realize their full power and authority in business and life.

For press inquiries, interviews, or speaking opportunities, please contact:

Phone: 949-358-3162 | Email: buildingfoundation.nvm@gmail.com | Instagram: @Dannielle.Godspeed

Facebook | Dannielle Godspeed

Media Contact
Company Name: Building Foundations LLC
Contact Person: Dannielle Thomas
Email: Send Email
City: Temecula
State: California
Country: United States
Website: buildingfoundationsllc.com

Synthetic Turf Northwest Leads the Way in Eco-Friendly Landscaping Solutions in the Pacific Northwest

Synthetic Turf Northwest Leads the Way in Eco-Friendly Landscaping Solutions in the Pacific Northwest

As environmental consciousness continues to shape decisions in homes, communities, and city planning, sustainable landscaping has emerged as a growing priority throughout the Pacific Northwest. Synthetic Turf Northwest, a locally owned leader in artificial turf installation since 1996, is proud to be at the forefront of this movement. With over two decades of experience, we offer durable, eco-friendly alternatives that meet both environmental needs and modern lifestyle demands.

With increasingly dry summers following traditionally wet winters, residents across Washington and Oregon are facing new challenges in maintaining lush, green lawns. Local utilities, such as Seattle Public Utilities and the Portland Water Bureau, often urge communities to reduce water use during seasonal dry periods. According to the EPA, traditional lawns guzzle up to 9 billion gallons of water every single day across the U.S.—a staggering figure that highlights the need for low-water alternatives.

That’s where Synthetic Turf Northwest steps in.

“Our customers want beautiful outdoor spaces without sacrificing sustainability,” says Mike VanDaveer, General Manager at Synthetic Turf Northwest. “We’ve built our reputation on quality, care, and forward-thinking solutions that serve both people and the planet.”

For more information, visit https://www.syntheticturfnorthwest.com/

A Smarter, Greener Alternative

Unlike natural grass, synthetic turf doesn’t require irrigation, making it an ideal choice for drought-prone areas and water-conscious households. From private homes to municipal green spaces and HOAs, Synthetic Turf Northwest helps communities cut down on excessive water usage without compromising curb appeal.

Beyond water savings, synthetic turf eliminates the need for gas-powered mowers and chemical fertilizers—two major contributors to urban pollution. That means no harmful runoff entering Puget Sound and safer environments for children, pets, and wildlife.

High-quality synthetic turf from Synthetic Turf Northwest is designed to withstand the test of time. With a lifespan of 10 to 15 years, it reduces material waste and minimizes the environmental impact of constant reseeding, sodding, and seasonal lawn maintenance.

As more Pacific Northwest homeowners, property managers, and community planners embrace green alternatives, Synthetic Turf Northwest remains committed to driving innovation in the field. Their expert team continues to offer custom solutions that strike a balance between functionality, aesthetics, and environmental responsibility.

“We’re not just transforming lawns—we’re helping transform communities,” says Mike VanDaveer. “By making small changes at home, we can all be part of a much bigger impact.”

About Synthetic Turf Northwest

Founded in 1996 and headquartered in Woodinville, WA, Synthetic Turf Northwest has provided thousands of customers with premium synthetic grass solutions. The company’s unwavering dedication to sustainability is evident in its innovative turf products that reduce water consumption, chemical usage, and carbon emissions — all while delivering beautiful, functional landscapes for homes, businesses, and public spaces.

Media Contact
Company Name: Synthetic Turf Northwest
Contact Person: Mike VanDaveer, CEO
Email: Send Email
Phone: 425-788-0718
Country: United States
Website: https://www.syntheticturfnorthwest.com/

Best Removal Company Edinburgh 2025 – Edinburgh Removals

Best Removal Companies 2025 for Home, Office and International, Small Moves

Edinburgh, Scotland – 15 August, 2025 – Edinburgh Removals, a trusted name in professional moving services, has been officially recognised as the Best Removal Company in Edinburgh for 2025, praised for delivering an excellent balance of care, price, and service. Known for achieving the highest ratings across Google, Trustpilot, and independent review platforms, the company works exclusively with verified and accredited moving partners. Offering both large-scale relocations and smaller, quick service needs, including same-day moves, Edinburgh Removals is the go-to choice for home removals, office moves, international relocations, packing services, and secure storage across Edinburgh and the UK.

Edinburgh Removals has built its reputation on providing stress-free, reliable, and competitively priced moving services in Edinburgh for both residential and commercial customers. The company’s extensive service range includes:

  • Home Removals Edinburgh – Full household relocations, flat and apartment moves, and specialist furniture handling.

  • Office Removals Edinburgh – Business and corporate relocation services, IT equipment transport, and minimal downtime planning.

  • International Removals from Edinburgh – Overseas moving solutions with professional packing, customs clearance, and door-to-door delivery.

  • Same-Day Removals Edinburgh – Urgent, last-minute moves within the city and to other UK locations.

  • Small Moves Edinburgh – Affordable single-item deliveries, student moves, and compact property relocations.

  • Packing Services Edinburgh – Full or partial packing, fragile item protection, and supply of quality packing materials.

  • Storage Services Edinburgh – Short-term and long-term secure storage for furniture, household goods, and business assets.

“Winning the Best Removal Company Edinburgh 2025 title is a reflection of our dedication to customer satisfaction,” said the Director of Edinburgh Removals. “We combine professional care with competitive pricing, ensuring every move – whether it’s a single-item delivery or an international relocation – is handled with precision, reliability, and a personal touch.”

What Makes Edinburgh Removals the Best in Edinburgh:

  • Top-Rated Service – 5-star reviews from hundreds of satisfied customers in Edinburgh and across Scotland.

  • Wide Coverage Area – From local moves within Edinburgh to long-distance UK relocations such as Edinburgh to London, Manchester, Birmingham, and Glasgow.

  • Accredited Partners – Working only with vetted, professional moving teams.

  • Transparent Pricing – No hidden fees, free no-obligation quotes, and clear communication throughout the process.

  • Eco-Friendly Initiatives – Reusable packing crates, recycling services, and efficient route planning to reduce emissions.

Whether moving locally within Edinburgh, relocating to another part of the UK, or transporting goods overseas, Edinburgh Removals delivers a tailored, stress-free experience that customers can trust.

Looking ahead, the company plans to expand its Edinburgh long-distance removal services, grow its international relocation network, and offer even faster same-day and next-day removal options to meet increasing demand.

About Edinburgh Removals

Edinburgh Removals is the leading provider of home removals, office relocations, international shipping, same-day removals, small moves, packing services, and storage solutions in Edinburgh, Scotland. Known for its high customer satisfaction ratings and commitment to service excellence, the company serves both local and long-distance moves across the UK and beyond.

Media Contact
Company Name: Edinburgh Removals
Contact Person: Robbie Allen
Email: Send Email
Country: United Kingdom
Website: https://www.edinburgh-removals.net/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Best Removal Company Edinburgh 2025 – Edinburgh Removals

Prostate Cancer Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | Telix Pharma, Merck, Orion Pharma, Exelixis, Ipsen Pharma and Takeda, Pfizer, AstraZeneca

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Prostate Cancer pipeline constitutes 140+ key companies continuously working towards developing 150+ Prostate Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Prostate Cancer Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Prostate Cancer Market.

 

The Prostate Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Prostate Cancer Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Prostate Cancer treatment therapies with a considerable amount of success over the years.

  • Prostate Cancer companies working in the treatment market are Telix Pharmaceuticals, Merck and Orion, Exelixis, Ipsen Pharma and Takeda, Pfizer, AstraZeneca, Kangpu Biopharmaceuticals, Merus, Blue Earth Therapeutics, and others, are developing therapies for the Prostate Cancer treatment

  • Emerging Prostate Cancer therapies in the different phases of clinical trials are- 177Lu-DOTA-rosopatamab (TLX591) IV infusion, Opevesostat (MK-5684; ODM-208) Oral, CABOMETYX (cabozantinib, XL184) Oral, Mevrometostat (PF-06821497) Oral, TRUQAP (Capivasertib) Oral, KPG-121 Oral, BIZENGRI (zenocutuzumab) IV, 177Lu-rhPSMA-10.1 IV, and others are expected to have a significant impact on the Prostate Cancer market in the coming years.

  • In June 2025, MSD and Daiichi Sankyo announced that the first patient has been dosed in the randomized Phase III IDeate-Prostate01 trial, comparing ifinatamab deruxtecan (I-DXd) with docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC). I-DXd, a potential first-in-class B7-H3-directed antibody-drug conjugate (ADC), was discovered by Daiichi Sankyo and is being co-developed with MSD. This open-label, multicenter trial is evaluating the ADC in mCRPC patients whose disease has progressed during or after treatment with an androgen receptor pathway inhibitor.

  • In June 2025, Novartis announced topline results from the pre-specified interim analysis of the Phase III PSMAddition trial, showing that Pluvicto (lutetium (177Lu) vipivotide tetraxetan) combined with standard of care (SoC) provided benefits in treating prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC). The open-label study met its primary endpoint, with the combination demonstrating radiographic progression-free survival (rPFS) benefits and a positive trend in overall survival (OS). In this trial, the SoC consisted of androgen receptor pathway inhibitor (ARPI) therapy plus androgen deprivation therapy (ADT).

  • In May 2025, Astellas Pharma Inc. (TSE: 4503) and Pfizer Inc. (NYSE: PFE) have announced long-term follow-up results from an open-label extension of the Phase 3 ARCHES (NCT02677896) study. The five-year data showed that men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with XTANDI™ (enzalutamide), an androgen receptor pathway inhibitor (ARPI), plus androgen deprivation therapy (ADT) had a 30% lower risk of death compared to those receiving placebo plus ADT. These findings will be presented in an oral session (Abstract #5005) at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

  • In February 2025, Israeli pharmaceutical company RedHill Biopharma launched a placebo-controlled Phase II trial to evaluate the combination of opaganib and darolutamide for treating metastatic castration-resistant prostate cancer (mCRPC). The study, involving 80 male participants, aims to assess whether opaganib can enhance the effectiveness of standard androgen receptor pathway inhibition (ARPI) therapy. This randomized trial also incorporates the PCPro lipid biomarker test to identify mCRPC patients with poor prognosis who may benefit from the combination treatment.

  • In February 2025, Mevrometostat, an EZH2 inhibitor, combined with enzalutamide and androgen deprivation therapy (ADT), demonstrated improved radiographic progression-free survival (rPFS) compared to enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC). These findings are from the dose expansion phase of a Phase 1b/2 clinical trial, presented at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (Abstract LBA138).

  • In the Phase III VISION study for PLUVICTO, the primary endpoints were Overall Survival (OS) and radiographic Progression-Free Survival (rPFS), with Overall Response Rate (ORR) by BICR included as an additional efficacy measure.

  • Another ongoing trial assessing capivasertib in combination with docetaxel aims to demonstrate superiority over placebo in terms of overall survival. Secondary outcome measures include radiographic Progression-Free Survival (rPFS) and Time to Pain Progression (TTPP).

 

Prostate Cancer Overview

Prostate cancer is a type of cancer that develops in the prostate, a small gland in men that produces seminal fluid. It often grows slowly and may not cause symptoms in early stages, but advanced cases can lead to urinary issues, pain, or spread to other parts of the body.

 

Get a Free Sample PDF Report to know more about Prostate Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/prostate-cancer-pipeline-insight

 

Emerging Prostate Cancer Drugs Under Different Phases of Clinical Development Include:

  • 177Lu-DOTA-rosopatamab (TLX591) IV infusion: Telix Pharmaceuticals

  • Opevesostat (MK-5684; ODM-208) Oral: Merck and Orion

  • CABOMETYX (cabozantinib, XL184) Oral: Exelixis, Ipsen Pharma and Takeda

  • Mevrometostat (PF-06821497) Oral: Pfizer

  • TRUQAP (Capivasertib) Oral: AstraZeneca

  • KPG-121 Oral: Kangpu Biopharmaceuticals

  • BIZENGRI (zenocutuzumab) IV: Merus

  • 177Lu-rhPSMA-10.1 IV: Blue Earth Therapeutics

 

Prostate Cancer Route of Administration

Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Prostate Cancer Molecule Type

Prostate Cancer Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

 

Prostate Cancer Pipeline Therapeutics Assessment

  • Prostate Cancer Assessment by Product Type

  • Prostate Cancer By Stage and Product Type

  • Prostate Cancer Assessment by Route of Administration

  • Prostate Cancer By Stage and Route of Administration

  • Prostate Cancer Assessment by Molecule Type

  • Prostate Cancer by Stage and Molecule Type

 

DelveInsight’s Prostate Cancer Report covers around 150+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Prostate Cancer product details are provided in the report. Download the Prostate Cancer pipeline report to learn more about the emerging Prostate Cancer therapies

 

Some of the key companies in the Prostate Cancer Therapeutics Market include:

Key companies developing therapies for Prostate Cancer are – MacroGenics, Syntrix Pharmaceuticals, Zenith Epigenetics, Xencor, Bristol Myers Squibb, Merus, Phosplatin Therapeutics, Laekna Therapeutics, Tavanta Therapeutics, Madison Vaccines, Taiho Pharmaceutical, Kangpu Biopharmaceuticals, Arvinas, Candel Therapeutics, Blue Earth Therapeutics, Ipsen Biopharmaceuticals, LAVA Therapeutics, Curium, Merck, Telix Pharmaceuticals, Exelixis, AstraZeneca, AB Science, Lantheus, Pfizer, Jiangsu Hengrui Pharmaceuticals, Modra Pharmaceuticals, Bristol-Myers Squibb, Essa Pharma, Poseida Therapeutics, Janux Therapeutics, Aurigene Oncology, Sathgen Therapeutics, Full-Life Technologies, NextPoint Therapeutics, AbbVie, SL VAXiGEN, Sorrento Therapeutics, Inc., 858 Therapeutics, Avacta Life Sciences Ltd, Nammi Therapeutics, BeiGene, DualityBio, and others.

 

Prostate Cancer Pipeline Analysis:

The Prostate Cancer pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Prostate Cancer with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Prostate Cancer Treatment.

  • Prostate Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Prostate Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Prostate Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Prostate Cancer drugs and therapies

 

Prostate Cancer Pipeline Market Drivers

  • The prostate cancer emerging pipeline consists of various novel molecules such as lorigerlimab an investigational, bispecific DART molecule that targets PD-1 and CTLA-4, CAN-2409 an oncolytic gene therapy among others.

  • The use of ADT primarily dominates the current treatment pattern for patients with prostate cancer. Although the sizable portion of the mCSPC market is captured by hormonal therapies, label expansion of XTANDI, NUBEQA, and ERLEADA for mCSPC are expected to help drive the overall market growth.

 

Prostate Cancer Pipeline Market Barriers

  • With a series of discouraging studies in recent years Merck’s KEYTRUDA and Bristol-Myers Squibb’s OPDIVO are struggling to make headway for its checkpoint inhibitors in prostate cancer.

  • Despite excellent double and triplet therapy options, novel targets and treatment development with enhanced prognostication for mCSPC patients is needed

 

Scope of Prostate Cancer Pipeline Drug Insight

  • Coverage: Global

  • Key Prostate Cancer Companies: Telix Pharmaceuticals, Merck and Orion, Exelixis, Ipsen Pharma and Takeda, Pfizer, AstraZeneca, Kangpu Biopharmaceuticals, Merus, Blue Earth Therapeutics, and others

  • Key Prostate Cancer Therapies: 177Lu-DOTA-rosopatamab (TLX591) IV infusion, Opevesostat (MK-5684; ODM-208) Oral, CABOMETYX (cabozantinib, XL184) Oral, Mevrometostat (PF-06821497) Oral, TRUQAP (Capivasertib) Oral, KPG-121 Oral, BIZENGRI (zenocutuzumab) IV, 177Lu-rhPSMA-10.1 IV, and others

  • Prostate Cancer Therapeutic Assessment: Prostate Cancer current marketed and Prostate Cancer emerging therapies

  • Prostate Cancer Market Dynamics: Prostate Cancer market drivers and Prostate Cancer market barriers

 

Request for Sample PDF Report for Prostate Cancer Pipeline Assessment and clinical trials

 

Table of Contents

1. Prostate Cancer Report Introduction

2. Prostate Cancer Executive Summary

3. Prostate Cancer Overview

4. Prostate Cancer- Analytical Perspective In-depth Commercial Assessment

5. Prostate Cancer Pipeline Therapeutics

6. Prostate Cancer Late Stage Products (Phase II/III)

7. Prostate Cancer Mid Stage Products (Phase II)

8. Prostate Cancer Early Stage Products (Phase I)

9. Prostate Cancer Preclinical Stage Products

10. Prostate Cancer Therapeutics Assessment

11. Prostate Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Prostate Cancer Key Companies

14. Prostate Cancer Key Products

15. Prostate Cancer Unmet Needs

16 . Prostate Cancer Market Drivers and Barriers

17. Prostate Cancer Future Perspectives and Conclusion

18. Prostate Cancer Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Prostate Cancer Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | Telix Pharma, Merck, Orion Pharma, Exelixis, Ipsen Pharma and Takeda, Pfizer, AstraZeneca

CYSM Explains How Body Shapers Are Becoming a Daily Confidence Boost for Women in 2025 Based on 30+ Years of Industry Presence

CYSM is a long-standing manufacturer of body shapers with 30+ years of industry presence and over a million verified customers.

After over 30 years of industry presence, decades of innovation, and over 1,000,000 satisfied customers, CYSM Shapers went public to discuss the technology that made one of the company’s best-sellers the “waist trainer women are talking about in 2025.”

CYSM started out crafting products in the surgery-recovery niche and has maintained the ethos that its shapers must be comfortable and even beneficial to health among people recovering from surgery.

That is why today’s CYSM lineup features items like the Waist Trainer, a product that scultps the user’s waist while also improving posture.

A company rep stated: “Our waist trainers feature advanced technology and premium materials, offering comfort and support for both everyday wear and exercise. Sculpt your figure, enhance performance, and enjoy versatile support whether you’re out and about or at the gym.”

Diving deep into CYSM’s secret of an hourglass shape, the team explained that every Waist Trainer features three-column hooks that allow a customized fit, mixed with gradual abdominal compression and a 360-degree latex band in thermal styles for full shaping.

CYMS noted on several occasions that inclusivity is at the very core of its catalog, which is why all shapers come in a wide range of sizes. Every product is also equipped with spiral-shaped inner supports and high-compression, high-durability fabric with no internal seams.

Thanks to the soft cotton lining, the CYSM Waist Trainer is approved for all-day wear. Still, the company managed to add ultra-compression fabric into the mix to support weight loss. “Our latex waist trainers are designed to boost thermal activity in your abdomen,” the team stated.

That way, the shaper helps its users trim inches from their waists while still supporting their figure. “These Waist Trainers intensify the effect on your midsection, promoting sweat and improving the fat-burning process – perfect for your body shaping and weight loss goals,” the company rep stated.

Focusing on the materials used in the process, CYSM explained that the product is made using 100% natural latex that has no other synthetic material. This promotes skincare but also boosts sweating to help the wearer burn fat and eliminate toxins. Thanks to the extra support, the Trainer promotes improved posture.

“Our waist trainers feature ergonomic rods designed to provide optimal back and lumbar support, which helps you maintain a proper posture throughout the day,” the team noted, describing the rods as lightweight and flexible so they can offer stability and allow freedom of movement.

“Not only do they protect your back health, but they also help prevent muscle strain,” the CYSM representative noted.

One of the staple pieces of tech behind CYSM Shapers is the exclusive Bio Therapy Technology, which adds microcapsules that release marine algae ingredients to the wearer’s skin upon contact. This infusion restores skin elasticity and boosts firmness and youthful vitality while also offering antibacterial protection and keeping the skin cool and fresh for extra comfort.

A satisfied customer named Tina wrote in her 5-star review of one of the best-selling CYSM Shapers: “I Love it! I was a little hesitant to get this as I’ve previously purchased other products of the like and had to return them because they were nothing like it was advertised. I purchased the Ultra Compressive Waist Cincher, and I love it.

“This company delivers quality and well-built products. The material is strong, feels soft to the skin, and compresses all the side and anterior bulges. I’ve been using mine for three weeks and I’m about to order a different style one. Follow the size chart at the bottom under customer service you’ll find the size assistant tab. Go ahead, buy without fear, you won’t be disappointed.”

More information about CYSM Shapers, the company’s history, technology, and the full product lineup, can all be found on the official website.

Media Contact
Company Name: CYSM Shapers
Contact Person: CYSM Team
Email: Send Email
Phone: +13235861600
Address:5807 Pacific Blvd
City: Huntington Park
State: CA 90255
Country: United States
Website: https://cysm.com/

One Eyed Jack’s to Host Grand Opening this Friday in Littleton, NC

Local Pirate-Themed Restaurant Sets Sail August 15th, Bringing Food, Fun, and a Splash of Adventure to Lake Gaston.

Ahoy, Lake Gaston! The wait is over- One Eyed Jack’s is officially opening it’s doors this Friday, August 15th, inviting locals and visitors to enjoy a full day of great food, lively atmosphere, and a unique experience from 11am to 10pm.

Locatedin the heart of Littleton, One Eyed Jack’s offers one-of-a-kind pirate themed setting, where guests can enjoy mouth watering dishes, cold drinks, and a family friendly environment that’s both adventurous and welcoming. With decor inspiried by the high seas and a menu crafted to satisfy every craving, this isn’t just another restaurant- its a treasure woirht finding.

“We wanted to create a place where friends, families, and visitors can relax, laugh, and enjoy a meal they’ll remember,” said Matthew Ferace, owner of One Eyed Jack’s. “From the moment you walk in, you’re part of the crew.”

Grand Opening Highlights:

• Full menu featuring signature dishes, local favorites, and themed coctails

• Pirate-themed decor and photo opportunities for all ages.

• Outdoor seating with views perfect for soaking in the Lake Gaston vibe.

Whether you’re a hungry landlubber or a seasoned lake adventurer, One Eyed Jack’s promises a fun-filled dining experience that blends local charm with swashbuckling style. Join us Friday, August 15th, 11am-10pm, and be part of the very first crew to step aboard this exciting new addition to the Littleton dining scene.

Location: 1865 Eaton Ferry Rd, Littleton, NC 27850

Join us on Facebook: https://www.facebook.com/profile.php?id=61575658089186

About One Eyed Jack’s:

One Eyed Jack’s is a locally owned, pirate-themed restaurant in Littleton, NC, serving delicious food, refreshing drinks, and good times for all. Located neear Lake Gaston, One Eyed Jack’s offers a lively and inviting atmosphere for both locals and visitors looking for a unique dining experience.

Media Contact
Company Name: MainIvent Advertising Agency
Contact Person: Michael Keesee
Email: Send Email
Phone: 7578128142
Address:908 Pecan Point Court
City: Chesapeake
State: VA
Country: United States
Website: www.mainivent.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: One Eyed Jack’s to Host Grand Opening this Friday in Littleton, NC

Crohn’s Disease Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, Bristol-Myers Squibb

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Crohn’s Disease pipeline constitutes 40+ key companies continuously working towards developing 50+ Crohn’s Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Crohn’s Disease Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Crohn’s Disease Market.

 

Crohn’s disease is a chronic inflammatory condition that primarily affects the gastrointestinal tract, causing inflammation anywhere from the mouth to the anus, but most commonly in the small intestine and the beginning of the large intestine (colon). It belongs to a group of conditions known as inflammatory bowel diseases (IBD).

 

Some of the key takeaways from the Crohn’s Disease Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Crohn’s Disease treatment therapies with a considerable amount of success over the years.

  • Crohn’s Disease companies working in the treatment market are Morphic Therapeutic, Orchard Therapeutics, Thetis Pharmaceuticals, AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, Bristol-Myers Squibb, Eisai Inc, Janssen Pharmaceutical, Eli Lilly and Company, Gilead Sciences, RedHill Biopharma, Celgene Corporation, AstraZeneca, and others, are developing therapies for the Crohn’s Disease treatment

  • Emerging Crohn’s Disease therapies in the different phases of clinical trials are- MORF 057, OTL-104, TP-317, AZD 7798, IMU 856, CBP-307, PF-06651600, Deucravacitinib, E6011, Guselkumab, Mirikizumab, Filgotinib, RHB-104, Ozanimod, Brazikumab, and others are expected to have a significant impact on the Crohn’s Disease market in the coming years.

  • In April 2025, Sanofi decided to discontinue the development of its oral tumour necrosis factor (TNF) inhibitor, balinatunfib, as a standalone treatment after it failed to meet the primary endpoint in a Phase II trial. Preliminary findings from the SPECIFIC-PSO Phase II study (NCT06073119) in psoriasis patients indicated that balinatunfib produced clinically meaningful improvements in the primary endpoint, PASI-75 response, with efficacy similar to other oral psoriasis treatments. However, it did not achieve statistical significance, which Sanofi attributed to “the nature of this limited Phase II study.” PASI-75 is a standard measure assessing whether a patient has achieved a 75% reduction in symptoms from baseline.

  • In March 2025, Agomab Therapeutics reported positive interim findings from 44 patients who completed treatment in the ongoing STENOVA1 Phase IIa trial of AGMB-129, an oral gastrointestinal (GI)-restricted small molecule ALK5 (TGF-β RI or ALK5) inhibitor being developed as a potential therapy for Fibrostenosing Crohn’s Disease (FSCD).

  • In March 2025, Celltrion announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), after receiving FDA approval in December 2024. STEQEYMA is authorized for the same indications as STELARA, ensuring reliable treatment options for both patients and healthcare providers.

  • In March 2025, Johnson & Johnson announced that the FDA has approved TREMFYA® (guselkumab), making it the first and only IL-23 inhibitor offering both subcutaneous (SC) and intravenous (IV) induction options for adults with moderately to severely active Crohn’s disease (CD), a chronic inflammatory condition affecting the gastrointestinal tract.

  • In February 2025, Eli Lilly shared findings from the VIVID-2 open-label extension study at the Crohn’s and Colitis Congress (CCC), revealing that most patients with moderately-to-severely active Crohn’s disease treated continuously with OMVOH for two years achieved sustained clinical and endoscopic outcomes, including 43.8% of patients who had previously failed biologic therapies.

  • In January 2025, The FDA approved OMVOH (mirikizumab) for Crohn’s disease, reinforcing the role of IL-23 inhibitors. Demonstrating robust long-term effectiveness, OMVOH is also under investigation for use in pediatric patients, potentially fulfilling a critical unmet need in this group.

 

Crohn’s Disease Overview

Crohn’s Disease is a chronic inflammatory bowel disease (IBD) that causes inflammation of the digestive tract, most commonly affecting the small intestine and the beginning of the colon. It can lead to symptoms such as abdominal pain, diarrhea, fatigue, weight loss, and malnutrition. The exact cause is unknown but is believed to involve an abnormal immune response, genetics, and environmental factors. Crohn’s can affect any part of the gastrointestinal tract and may lead to complications like strictures, fistulas, or bowel obstruction. While there is no cure, treatments including medications, dietary changes, and sometimes surgery can help manage symptoms and inflammation.

 

Get a Free Sample PDF Report to know more about Crohn’s Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/crohns-disease-cd-pipeline-insight

 

Emerging Crohn’s Disease Drugs Under Different Phases of Clinical Development Include:

  • MORF 057: Morphic Therapeutic

  • OTL-104: Orchard Therapeutics

  • TP-317: Thetis Pharmaceuticals

  • AZD 7798: AstraZeneca

  • IMU 856: Immunic

  • CBP-307: Suzhou Connect Biopharmaceuticals

  • PF-06651600: Pfizer

  • Deucravacitinib: Bristol-Myers Squibb

  • E6011: Eisai Inc

  • Guselkumab: Janssen Pharmaceutical

  • Mirikizumab: Eli Lilly and Company

  • Filgotinib: Gilead Sciences

  • RHB-104: RedHill Biopharma

  • Ozanimod: Celgene Corporation

  • Brazikumab: AstraZeneca

 

Crohn’s Disease Route of Administration

Crohn’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Crohn’s Disease Molecule Type

Crohn’s Disease Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins

  • Small molecule

  • Monoclonal antibody

  • Peptide

  • Polymer

  • Gene therapy

 

Crohn’s Disease Pipeline Therapeutics Assessment

  • Crohn’s Disease Assessment by Product Type

  • Crohn’s Disease By Stage and Product Type

  • Crohn’s Disease Assessment by Route of Administration

  • Crohn’s Disease By Stage and Route of Administration

  • Crohn’s Disease Assessment by Molecule Type

  • Crohn’s Disease by Stage and Molecule Type

 

DelveInsight’s Crohn’s Disease Report covers around 50+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Crohn’s Disease product details are provided in the report. Download the Crohn’s Disease pipeline report to learn more about the emerging Crohn’s Disease therapies

 

Some of the key companies in the Crohn’s Disease Therapeutics Market include:

Key companies developing therapies for Crohn’s Disease are – Janssen, RedHill Biopharma, Amgen, Pfizer, Prometheus Biosciences, AgomAb Therapeutics, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, HAV Vaccines Ltd, Enzo Biochem Inc., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Pfizer, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Pfizer, Atlantic Healthcare, 4D Pharma, and others.

 

Crohn’s Disease Pipeline Analysis:

The Crohn’s Disease pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Crohn’s Disease with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Crohn’s Disease Treatment.

  • Crohn’s Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Crohn’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Crohn’s Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Crohn’s Disease drugs and therapies

 

Crohn’s Disease Pipeline Market Drivers

  • High prevalence of Crohn’s Disease, increase in Drug Development for Crohn’s treatment, change in lifestyle patterns are some of the important factors that are fueling the Crohn’s Disease Market.

 

Crohn’s Disease Pipeline Market Barriers

  • However, lack of early diagnosis of the disease, high cost associated with the treatment and other factors are creating obstacles in the Crohn’s Disease Market growth.

 

Scope of Crohn’s Disease Pipeline Drug Insight

  • Coverage: Global

  • Key Crohn’s Disease Companies: Morphic Therapeutic, Orchard Therapeutics, Thetis Pharmaceuticals, AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, Bristol-Myers Squibb, Eisai Inc, Janssen Pharmaceutical, Eli Lilly and Company, Gilead Sciences, RedHill Biopharma, Celgene Corporation, AstraZeneca, and others

  • Key Crohn’s Disease Therapies: MORF 057, OTL-104, TP-317, AZD 7798, IMU 856, CBP-307, PF-06651600, Deucravacitinib, E6011, Guselkumab, Mirikizumab, Filgotinib, RHB-104, Ozanimod, Brazikumab, and others

  • Crohn’s Disease Therapeutic Assessment: Crohn’s Disease current marketed and Crohn’s Disease emerging therapies

  • Crohn’s Disease Market Dynamics: Crohn’s Disease market drivers and Crohn’s Disease market barriers

 

Request for Sample PDF Report for Crohn’s Disease Pipeline Assessment and clinical trials

 

Table of Contents

1. Crohn’s Disease Report Introduction

2. Crohn’s Disease Executive Summary

3. Crohn’s Disease Overview

4. Crohn’s Disease- Analytical Perspective In-depth Commercial Assessment

5. Crohn’s Disease Pipeline Therapeutics

6. Crohn’s Disease Late Stage Products (Phase II/III)

7. Crohn’s Disease Mid Stage Products (Phase II)

8. Crohn’s Disease Early Stage Products (Phase I)

9. Crohn’s Disease Preclinical Stage Products

10. Crohn’s Disease Therapeutics Assessment

11. Crohn’s Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Crohn’s Disease Key Companies

14. Crohn’s Disease Key Products

15. Crohn’s Disease Unmet Needs

16 . Crohn’s Disease Market Drivers and Barriers

17. Crohn’s Disease Future Perspectives and Conclusion

18. Crohn’s Disease Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Crohn’s Disease Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, Bristol-Myers Squibb

Best Japanese Learning App 2025: Migaku Wins Top Honor

Migaku named #1 Japanese Learning App for 2025! Immersion tools, native content, and personalized study paths for faster fluency.

Migaku is proud to announce its recognition as the Best Japanese Learning App of 2025 by a panel of language learning experts and educators. Built for learners committed to reaching fluency, Migaku offers an unmatched blend of immersion tools, authentic content, structured support, and personalized feedback to accelerate learning.

Migaku stands out by turning the media you already engage with—Netflix, YouTube, articles—into customized lessons. The browser extension and mobile app let learners click any Japanese word to see definitions, AI-powered breakdowns, context, audio, and visuals, and turn that directly into flashcards with a single click.

Learners can start with guided courses such as Migaku Fundamentals, which prepares beginners to read and pronounce Japanese scripts, and Migaku Academy, which teaches the most frequent vocabulary and essential grammar points—enough to understand the majority of dialogue in everyday media. Each flashcard introduces just one new piece of information and uses spaced repetition to ensure long-term retention.

Migaku tracks your known words and comprehension across content, recommending material that matches your skill level based on measurable data. Learners worldwide praise the platform’s flexibility, immersive experience, and efficiency, often reporting faster progress than with traditional study methods.

As the Best Japanese Learning App in 2025, Migaku continues to innovate with features like AI-generated subtitles, auto-pause controls, enhanced playback options, and improved media browsing tools. These updates make sentence mining and vocabulary acquisition even more seamless.

Whether the goal is passing the JLPT, working in Japan, or enjoying Japanese media without subtitles, Migaku provides a proven, engaging path to fluency.

About Migaku:

Migaku is a complete language learning platform that lets users learn through the content they love. Supporting multiple languages, it combines browser and mobile apps with interactive tools, AI-assisted learning, and progress tracking. Migaku transforms movies, anime, websites, books, and more into immersive, effective language lessons.

Media Contact
Company Name: Migaku Inc.
Contact Person: Matteo Sanzone
Email: Send Email
City: Tokyo
Country: Japan
Website: migaku.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Best Japanese Learning App 2025: Migaku Wins Top Honor

Hemorrhoids Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Citius Pharma, Nivagen Pharma, Edesa Biotech

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Hemorrhoids pipeline constitutes 3+ key companies continuously working towards developing 3+ Hemorrhoids treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

The Hemorrhoids Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Hemorrhoids Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hemorrhoids Market.

 

Some of the key takeaways from the Hemorrhoids Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Hemorrhoids treatment therapies with a considerable amount of success over the years. Hemorrhoids Key players such as – Edesa Biotech, Citius Pharmaceuticals, Nivagen Pharmaceuticals Inc., and others, are developing therapies for the Hemorrhoids treatment

  • Hemorrhoids Emerging therapies such as – EB02, Halo-Lido, Hydrocortisone Acetate Suppository, and others are expected to have a significant impact on the Hemorrhoids market in the coming years.

  • In November 2024, Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company focused on developing and commercializing first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy, for its initial indication in treating cutaneous T-cell lymphoma. The company’s late-stage pipeline features Mino-Lok®, an antibiotic lock solution designed to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation aimed at relieving hemorrhoids. Both a Pivotal Phase 3 trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023, with Mino-Lok achieving its primary and secondary endpoints in the Phase 3 study.

  • In June 2023, Citius Pharmaceuticals applied for patents for the formulations of Halo-Lido (CITI-002) hemorrhoid cream following an assessment of the Phase IIb trial outcomes.

 

Hemorrhoids Overview

Hemorrhoids, also known as piles, are swollen and inflamed veins located in the lower rectum and anus. They can cause discomfort, pain, and bleeding, especially during bowel movements. Hemorrhoids are classified into two types based on their location: internal hemorrhoids and external hemorrhoids.

 

Get a Free Sample PDF Report to know more about Hemorrhoids Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/hemorrhoids-pipeline-insight

 

Route of Administration

Hemorrhoids pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravitreal

  • Subretinal

  • Topical

  • Molecule Type

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

  • Product Type

 

Hemorrhoids Pipeline Therapeutics Assessment

  • Hemorrhoids Assessment by Product Type

  • Hemorrhoids By Stage and Product Type

  • Hemorrhoids Assessment by Route of Administration

  • Hemorrhoids By Stage and Route of Administration

  • Hemorrhoids Assessment by Molecule Type

  • Hemorrhoids by Stage and Molecule Type

 

DelveInsight’s Hemorrhoids Report covers around 3+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Some of the key companies in the Hemorrhoids Therapeutics Market include:

Key companies developing therapies for Hemorrhoids are – Johnson & Johnson, Boston Scientific Corporation, Medtronic plc, CONMED Corporation, Cook Medical, Sklar Surgical Instruments, Integra LifeSciences Corporation, Surkon Medical Co., Ltd., and Medline Industries, Inc., and others.

 

Emerging Hemorrhoids Drugs Under Different Phases of Clinical Development Include:

  • EB02: Edesa Biotech

  • Halo-Lido: Citius Pharmaceuticals

  • Hydrocortisone Acetate Suppository: Nivagen Pharmaceuticals Inc.

 

Download Sample PDF Report to know more about Hemorrhoids drugs and therapies

 

Hemorrhoids Pipeline Analysis:

The Hemorrhoids pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Hemorrhoids with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemorrhoids Treatment.

  • Hemorrhoids key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Hemorrhoids Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hemorrhoids market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Hemorrhoids product details are provided in the report. Download the Hemorrhoids pipeline report to learn more about the emerging Hemorrhoids therapies

 

Hemorrhoids Pipeline Market Drivers

  • Rise in awareness about hemorrhoids

  • Increase in reported cases of hemorrhoids

 

Hemorrhoids Pipeline Market Barriers

  • Lack of specialized personnel and healthcare infrastructure for the treatment of hemorrhoids

  • The time taking treatment procedure is also a hindrance to the growth of the hemorrhoids treatment market

 

Scope of Hemorrhoids Pipeline Drug Insight

  • Coverage: Global

  • Key Hemorrhoids Companies: Edesa Biotech, Citius Pharmaceuticals, Nivagen Pharmaceuticals Inc., and others

  • Key Hemorrhoids Therapies: EB02, Halo-Lido, Hydrocortisone Acetate Suppository, and others

  • Hemorrhoids Therapeutic Assessment: Hemorrhoids current marketed and Hemorrhoids emerging therapies

  • Hemorrhoids Market Dynamics: Hemorrhoids market drivers and Hemorrhoids market barriers

 

Request for Sample PDF Report for Hemorrhoids Pipeline Assessment and clinical trials

 

Table of Contents

1

Hemorrhoids Report Introduction

2

Hemorrhoids Executive Summary

3

Hemorrhoids Overview

4

Hemorrhoids- Analytical Perspective In-depth Commercial Assessment

5

Hemorrhoids Pipeline Therapeutics

6

Hemorrhoids Late Stage Products (Phase II/III)

7

Hemorrhoids Mid Stage Products (Phase II)

8

Hemorrhoids Early Stage Products (Phase I)

9

Hemorrhoids Preclinical Stage Products

10

Hemorrhoids Therapeutics Assessment

11

Hemorrhoids Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Hemorrhoids Key Companies

14

Hemorrhoids Key Products

15

Hemorrhoids Unmet Needs

16

Hemorrhoids Market Drivers and Barriers

17

Hemorrhoids Future Perspectives and Conclusion

18

Hemorrhoids Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hemorrhoids Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Citius Pharma, Nivagen Pharma, Edesa Biotech

DUB Inhibitors Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Mission Therapeutics, Ubiquigent, Almac Discovery, KSQ Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, DUB Inhibitors pipeline constitutes key companies continuously working towards developing DUB Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“DUB Inhibitors Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the DUB Inhibitors Market.

 

The DUB Inhibitors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the DUB Inhibitors Pipeline Report:

  • Companies across the globe are diligently working toward developing novel DUB Inhibitors treatment therapies with a considerable amount of success over the years.

  • DUB Inhibitors companies working in the treatment market are bromide Cothera, USP7 Ubiquigent, Carmot Therapeutics, Molecure, Mission Therapeutics, Tango Therapeutics, Mission Therapeutics, KSQ Therapeutics, Cothera Bioscience, Almac Discovery, Carmot Therapeutics, Progenra, Vivolux, and others, are developing therapies for the DUB Inhibitors treatment

  • Emerging DUB Inhibitors therapies in the different phases of clinical trials are- Sepantronium, Research program, Small molecules, OAT-4828, MTX325, TNG348, MTX652, KSQ-4279, PC-002, USP30 inhibitor program, USP7 inhibitors program, Research programme: deubiquitinating enzyme inhibitors, MuRF1 inhibitors, VLX1570, and others are expected to have a significant impact on the DUB Inhibitors market in the coming years.

  • The emerging pipeline for DUB inhibitors is varied, featuring several promising candidates such as ISM-3091 (InSilico Medicine), OAT-4828 (Molecure), KSQ-4279 (KSQ Therapeutics/Roche), MTX652 and MTX325 (Mission Therapeutics), sepantronium bromide/PC-002/YM155 (Cothera Bioscience), TNG348 (Tango Therapeutics), ASN3186/AT012 (Asieris Pharmaceuticals), among others. Most of these candidates are currently in the early stages of development, either preclinical or Phase I.

  • In July 2024, Mission Therapeutics has received USD 5.2 million in funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Parkinson’s UK to support the development of its potential disease-modifying Parkinson’s treatment, MTX325.

  • In July 2024, Molecure formed a strategic research partnership with Avicenna Biosciences to advance the discovery and development of innovative small-molecule drugs targeting USP7.

 

DUB Inhibitors Overview

DUB inhibitors, or deubiquitinase inhibitors, are a class of compounds that target enzymes called deubiquitinases (DUBs). These enzymes are responsible for removing ubiquitin molecules from proteins, a process known as deubiquitination. Ubiquitination and deubiquitination play essential roles in regulating various cellular processes, including protein degradation, DNA repair, signal transduction, and immune response.

 

Get a Free Sample PDF Report to know more about DUB Inhibitors Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/dub-inhibitors-market

 

Emerging DUB Inhibitors Drugs Under Different Phases of Clinical Development Include:

  • Sepantronium: bromide Cothera

  • Research program: USP7 Ubiquigent

  • Small molecules: Carmot Therapeutics

  • OAT-4828: Molecure

  • MTX325: Mission Therapeutics

  • TNG348: Tango Therapeutics

  • MTX652: Mission Therapeutics

  • KSQ-4279: KSQ Therapeutics

  • PC-002: Cothera Bioscience

  • USP30 inhibitor program: Mission Therapeutics

  • USP7 inhibitors program: Almac Discovery

  • Research programme: deubiquitinating enzyme inhibitors: Carmot Therapeutics

  • MuRF1 inhibitors: Progenra

  • VLX1570: Vivolux

 

DUB Inhibitors Pipeline Therapeutics Assessment

  • DUB Inhibitors Assessment by Product Type

  • DUB Inhibitors By Stage and Product Type

  • DUB Inhibitors Assessment by Route of Administration

  • DUB Inhibitors By Stage and Route of Administration

  • DUB Inhibitors Assessment by Molecule Type

  • DUB Inhibitors by Stage and Molecule Type

 

DelveInsight’s DUB Inhibitors Report covers around products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further DUB Inhibitors product details are provided in the report. Download the DUB Inhibitors pipeline report to learn more about the emerging DUB Inhibitors therapies

 

Some of the key companies in the DUB Inhibitors Therapeutics Market include:

Key companies developing therapies for DUB Inhibitors are – Mission Therapeutics, Ubiquigent, Almac Discovery, KSQ Therapeutics, Carmot Therapeutics, Progenra, Hybrigenics, and others.

 

DUB Inhibitors Pipeline Analysis:

The DUB Inhibitors pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of DUB Inhibitors with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for DUB Inhibitors Treatment.

  • DUB Inhibitors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • DUB Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the DUB Inhibitors market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about DUB Inhibitors drugs and therapies

 

DUB Inhibitors Pipeline Market Drivers

  • Novel candidates for target-directed drug development, DUBs play major roles in diverse cellular-processes are some of the important factors that are fueling the DUB Inhibitors Market.

 

DUB Inhibitors Pipeline Market Barriers

  • However, lack of in-depth studies to understand their natural regulatory mechanisms, inhibitors developed could have severe adverse effects by affecting non-target pathways and other factors are creating obstacles in the DUB Inhibitors Market growth.

 

Scope of DUB Inhibitors Pipeline Drug Insight

  • Coverage: Global

  • Key DUB Inhibitors Companies: bromide Cothera, USP7 Ubiquigent, Carmot Therapeutics, Molecure, Mission Therapeutics, Tango Therapeutics, Mission Therapeutics, KSQ Therapeutics, Cothera Bioscience, Almac Discovery, Carmot Therapeutics, Progenra, Vivolux, and others

  • Key DUB Inhibitors Therapies: Sepantronium, Research program, Small molecules, OAT-4828, MTX325, TNG348, MTX652, KSQ-4279, PC-002, USP30 inhibitor program, USP7 inhibitors program, Research programme: deubiquitinating enzyme inhibitors, MuRF1 inhibitors, VLX1570, and others

  • DUB Inhibitors Therapeutic Assessment: DUB Inhibitors current marketed and DUB Inhibitors emerging therapies

  • DUB Inhibitors Market Dynamics: DUB Inhibitors market drivers and DUB Inhibitors market barriers

 

Request for Sample PDF Report for DUB Inhibitors Pipeline Assessment and clinical trials

 

Table of Contents

1. DUB Inhibitors Report Introduction

2. DUB Inhibitors Executive Summary

3. DUB Inhibitors Overview

4. DUB Inhibitors- Analytical Perspective In-depth Commercial Assessment

5. DUB Inhibitors Pipeline Therapeutics

6. DUB Inhibitors Late Stage Products (Phase II/III)

7. DUB Inhibitors Mid Stage Products (Phase II)

8. DUB Inhibitors Early Stage Products (Phase I)

9. DUB Inhibitors Preclinical Stage Products

10. DUB Inhibitors Therapeutics Assessment

11. DUB Inhibitors Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. DUB Inhibitors Key Companies

14. DUB Inhibitors Key Products

15. DUB Inhibitors Unmet Needs

16 . DUB Inhibitors Market Drivers and Barriers

17. DUB Inhibitors Future Perspectives and Conclusion

18. DUB Inhibitors Analyst Views

19. Appendix

20. About DelveInsight

Latest Reports:

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: DUB Inhibitors Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Mission Therapeutics, Ubiquigent, Almac Discovery, KSQ Therapeutics